<DOC>
	<DOCNO>NCT00486044</DOCNO>
	<brief_summary>The purpose study see simvastatin , cholesterol-lowering drug , affect process related development Alzheimer 's disease , include : 1 ) level substance call beta-amyloid-42 find spinal fluid surround brain , 2 ) blood flow brain , 3 ) inflammation brain , 4 ) cognitive function .</brief_summary>
	<brief_title>Evaluating Simvastatin 's Potential Role Therapy</brief_title>
	<detailed_description>Some study suggest statin medication , group cholesterol-lowering medicine , may help prevent Alzheimer 's disease . However , proven human . The purpose study see simvastatin affect substance spinal fluid around brain call beta-amyloid-42 thought contribute Alzheimer 's disease . This study also evaluate whether simvastatin improve regional brain blood flow ( magnetic resonance image [ MRI ] ) , reduce inflammation , improve cognitive function . The ESPRIT study 9-month randomized , control clinical trial randomize 100 middle-aged adult parental history Alzheimer 's disease . Participants randomize simvastatin 40 mg one month 80 mg daily match placebo tablet . Fifty ESPRIT subject participate MRI sub-study . Participants follow data collect : fasting blood test ( baseline month 3 9 ) , medical history medication questionnaire ( visit ) , study medication side effect review ( visit ) , lumbar puncture procedure ( baseline month 9 ) , memory testing ( baseline month 3 9 ) , MRI ( baseline month 9 50 sub-study participant ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Age 35 69 Parent Alzheimer 's disease Current use cholesterollowering medication Active liver disease History adverse reaction statin Contraindication lumbar puncture Elevated lab value ( creatine kinase creatinine ) Use medication know interact statin History dementia Currently pregnant plan become pregnant Use large quantity grapefruit juice ( 1 quart per day ) Current involvement another investigational drug study Contraindications MRI ( MRI substudy ) Ethical contraindication placebo ( person high vascular risk )</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>amyloid protein</keyword>
	<keyword>apolipoprotein</keyword>
	<keyword>cerebrospinal fluid</keyword>
	<keyword>cerebrovascular circulation</keyword>
	<keyword>inflammation</keyword>
	<keyword>magnetic resonance imaging</keyword>
	<keyword>prevention &amp; control</keyword>
</DOC>